BSX - Boston Scientific Corporation
| Previous Close | 42.25 |
| Open | 42.47 |
| Bid | 42.52 x 800 |
| Ask | 42.53 x 1800 |
| Day's Range | 42.31 - 42.75 |
| 52 Week Range | 31.56 - 43.66 |
| Volume | 1,821,904 |
| Avg. Volume | 7,647,688 |
| Market Cap | 59.235B |
| Beta (3Y Monthly) | 0.71 |
| PE Ratio (TTM) | 33.28 |
| EPS (TTM) | 1.28 |
| Earnings Date | Jul 24, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.55 |
- Zacks•2 hours ago
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
- Zacks•4 days ago
Will USTR's 25% Tariff Exemption Spell Relief for MedTech?
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
- Investor's Business Daily•5 days ago
These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
- Zacks•5 days ago
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•5 days ago
US-India Trade Tensions Rise: 3 Stocks in the Line of Fire
As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.
- Zacks•10 days ago
Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD
The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.
- Zacks•11 days ago
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
- Zacks•12 days ago
Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
- Zacks•12 days ago
Boston Scientific's Global Growth Robust Amid Currency Woe
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Boston Scientific Corp.
Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $3.26 billion over the last one-month into ETFs that hold BSX are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BSX credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•14 days ago
Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.
- Simply Wall St.•14 days ago
Here's Why I Think Boston Scientific (NYSE:BSX) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- Zacks•17 days ago
Edwards Lifesciences Recalls Heart Device on Balloon Rupture
Shares of Edwards Lifesciences (EW) decline post product recall news.
- TipRanks•18 days ago
3 Healthcare Stocks Ready to Grow
2019 has been a rocky year for the healthcare industry. The general healthcare market sell-off combined with criticism over high costs poses a cause for concern. Despite the lackluster performance of many healthcare stocks so far in 2019, there are a few standouts with long-term growth potential. Using data from TipRanks, we’ve narrowed down three stocks in the healthcare space that analysts believe are well positioned for future growth. Boston Scientific Corporation (BSX)Unlike other stocks in the healthcare industry, Boston Scientific shares saw significant growth over the last year. The medical equipment manufacturer’s stock increased 22.5% while the industry as a whole saw only a 4% increase. In the quarter ending March 31, the company reported calendar year increases in revenue and net profit. Revenue was up from $2.38 billion to $2.49 billion while net profit increased from $298 million to $424 million.Boston Scientific’s long-term growth plan, which includes projections of double digit adjusted EPS growth through 2020, gives analysts reason to believe the company will continue to outperform. Raj Denhoy, a top analyst from Jeffries, raised his price target from $44 to $48 stating that the company’s projections from their investor meeting were “another positive look at a story that has been in sharp ascendancy for the last five years.” He added that the projections are even somewhat conservative given the company’s stability and the addition of new products in the next few quarters. Another five-star analyst, Matt Miksi of Credit Suisse, explained that he is unsurprised by Boston’s success when discussing the company’s sale of various products from their portfolio to Varian for $90 million. He maintained the stock’s Outperform rating and $45.00 price target, indicating a 5.56% upside. The Street’s outlook on the stock is bullish, with 10 analysts from TipRanks giving a buy rating vs just 1 hold over the last three months. The stock boasts a ‘Strong Buy’ analyst consensus and an average price target of $45.63, suggesting a 7.04% upside. View BSX Price Target & Analyst Rating Details Invitae Corporation (NVTA)Invitae is an innovative biotech company in the genetic testing segment of the market whose goal is to make genetic screenings more affordable and accessible. Five-star financial blogger, Todd Campbell, notes that the company cut the cost of goods sold by upwards of 20% over the last year as well as reported year-over-year sales of $148 million, a 117% increase. Management is projecting sales of $220 million in 2019 and a test volume of 500,000. Additionally, the company announced on June 17 that they are set to acquire Singular Bio. “The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year,” stated Sean George, the company’s CEO. Five-star rated Cowen & Co. analyst, Doug Schenkel, is confident in the stocks ability to grow, reiterating his Outperform rating and $30.00 price target. He believes Singular Bio’s “flexible, quick, and less expensive technology will give Invitae a competitive advantage over other companies with sequencing-based and microarray-based approaches for some applications including NIPS/NIPT.”The consensus among analysts is that the stock is a ‘Strong Buy’, with an average price target of $30.00, suggesting a 23.61% upside. View NVTA Price Target & Analyst Rating Details Teladoc Health, Inc. (TDOC)The last stock on our list doesn’t appear to be slowing down any time soon. Teladoc meets the growing demand for healthcare access in a cost-effective way by providing virtual medical care through telephone and videoconferencing technology. Share prices surged by 35.73% year-to-date. Management is confident that this growth will continue throughout the rest of the year. Based on Teladoc’s recent acquisitions as well as their competitive advantage within this segment of the healthcare sector, management is anticipating 37% revenue growth. In the most recent quarter, the company reported 29% organic growth with 1,063,000 total visits. Richard Close, an analyst at Canaccord Genuity, believes that the telemedicine company’s “penetration into its existing client base will allow it to generate robust organic growth.” He maintains his buy rating on the stock and price target of $95.00 (41.20% upside). Five-star Piper Jaffray analyst, Sean Wieland, remains bullish on the stock. He explained that he views the completion of their CFO search and an impending United deal as “two important catalysts and remains a buyer of the stock in front of them.” He reiterated his Overweight rating and price target of $86.00, suggesting a 27.82% upside.While the on-demand remote medical care provider isn’t profitable yet, analysts believe in Teladoc’s growth potential. The stock has a ‘Strong Buy’ analyst consensus, with 12 out of 13 analysts on TipRanks giving a buy rating. The average price target of $79.83 shows that analysts believe the stock price could increase by 18.65%. View TDOC Price Target & Analyst Rating DetailsFind your own best investment with TipRanks’ Analysts’ Top Stocks page.
- Zacks•19 days ago
Varian to Acquire Boston Scientific's Embolic Bead Products
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
- American City Business Journals•19 days ago
Analysts bullish on Boston Scientific's plans for 75 new products by 2022
Boston Scientific CEO Michael Mahoney laid out the long-term strategy for the company late last week, including a plan to launch 75 new cardiac valve, brain stimulation and other products by 2022.
- Benzinga•20 days ago
Varian Will Acquire Embolic Bead Asset From Boston Scientific
Varian Medical Systems (NYSE: VAR ) will acquire Boston Scientific’s (NYSE: BSX ) portfolio of drug-loadable microsphere and bland embolic bead products. Terms of the transaction were not disclosed. Boston ...
- Insider Monkey•20 days ago
Marshall Wace’s Return, AUM, and Holdings (Part II)
Read the beginning of this article here. At the end of March 2019, Marshall Wace held the most valuable position in Zoetis Inc. (NYSE:ZTS), the biggest producer of vaccinations and medicine for livestock and pets that was once a part of the world’s biggest drug maker, Pfizer. The company has a market cap of $54.81 […]
- PR Newswire•21 days ago
Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results
MARLBOROUGH, Mass. , July 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ...
- GuruFocus.com•24 days ago
Boston Scientific May Be Too Rich for Johnson & Johnson
Market value of medical device maker up nearly 30% since December
- PR Newswire•24 days ago
Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group
ARTARMON, Australia , June 28, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that it has secured $75 million in equity financing from Boston Scientific Corporation ...
- Investor's Business Daily•25 days ago
Why This Medtech Stock Could Top Its Own Bullish 3-Year Outlook
Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.
- Zacks•25 days ago
Boston Scientific Strong on Growth Goals and Future Launches
This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.
- PR Newswire•26 days ago
Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day
MARLBOROUGH, Mass., June 26, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline and strategic investments to enable improved clinical and economic outcomes, sustain category leadership in served markets and expand into high-growth, adjacent markets to deliver strong financial performance across the company's MedSurg, Rhythm and Neuro, and Cardiovascular segments. "This is an exciting time for Boston Scientific to help more patients live better and longer lives through the benefits provided by our current medical devices and treatment therapies, while we invest in and develop a robust, long-term pipeline of future technologies," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
